12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fenretinide: Additional Phase IIb data

Additional data from a 24-month, double-blind Phase IIb trial in 246 patients showed that 100 and 300 mg once-daily oral fenretinide led to median GA lesion growth rates of 12.2% and 11.4%, respectively, vs. 14.5% for placebo at 6 months. At 12 months, patients receiving low- or high-dose fenretinide had median GA lesion growth rates of 26.3% and 21.4%, respectively,...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >